Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Novo Nordisk’s blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including ...

It hasn't been a great period for investors in Novo Nordisk (NYSE: NVO) despite its ongoing status as one of the ...